Research Blog
Expert analysis, breaking news, and informed commentary on retatrutide research, clinical trial updates, conference presentations, and regulatory milestones.
The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches
Where obesity treatment is headed — the evolution from GLP-1 monotherapy to multi-receptor agonists and combination strategies, and where retatrutide fits in the expanding pipeline.
Retatrutide Dose Escalation Explained: Why Starting Low Matters
Understanding dose escalation in retatrutide and other GLP-1 class drugs — how gradual titration improves tolerability, what the Phase 2 trial revealed, and implications for clinical practice.
Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant
An in-depth analysis of retatrutide's approximately 82% liver fat reduction in Phase 2 — what it means for MASLD treatment, why glucagon receptor agonism drives the effect, and how it compares to other therapeutic approaches.
Putting 24% Weight Loss in Context: What Retatrutide's Numbers Mean
What does 24.2% mean body weight loss actually look like in clinical practice? Contextualizing retatrutide data against bariatric surgery, lifestyle intervention, and responder analysis.
Retatrutide FDA Approval Timeline: When Will Retatrutide Be Available?
Evidence-based analysis of retatrutide's FDA approval timeline as of March 2026, including Phase 3 TRIUMPH program status, TRIUMPH-4 results (-28.7% weight loss), expected NDA filing date, FDA review process, and realistic availability projections for 2027-2028.
Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets
How Eli Lilly is developing both tirzepatide (Mounjaro/Zepbound) and retatrutide — examining dual vs. triple agonism, clinical differentiation, and portfolio strategy.
Retatrutide vs. Wegovy: What the Data Actually Shows
A cross-trial comparison of retatrutide and semaglutide 2.4 mg (Wegovy), examining weight loss efficacy, mechanism differences, and the limitations of indirect comparisons.
Retatrutide Side Effects: What Clinical Studies Actually Show
A factual, evidence-based summary of adverse events reported in retatrutide Phase 1 and Phase 2 clinical trials — gastrointestinal effects, dose-dependent patterns, discontinuation rates, and how they compare to other incretin-based therapies.
The TRIUMPH Phase 3 Program: Everything We Know
A comprehensive guide to Eli Lilly's TRIUMPH clinical trial program for retatrutide — individual trial designs, enrollment targets, primary endpoints, expected timelines, and what it all means for potential regulatory approval.
Why the Glucagon Receptor Matters: The Third Component of Triple Agonism
An analysis of why adding glucagon receptor agonism to GLP-1 and GIP activity makes retatrutide mechanistically distinct — and how glucagon's effects on energy expenditure, liver fat metabolism, and thermogenesis may drive superior clinical outcomes.
What Phase 3 Means: Understanding the TRIUMPH Program
An explanation of what Phase 3 clinical trials represent in drug development, what the TRIUMPH program is designed to answer, and what stakeholders should expect from retatrutide's pivotal trials.
Why Triple Agonism Matters: The Next Frontier in Metabolic Medicine
An analysis of why targeting three metabolic hormone receptors simultaneously represents a meaningful advancement over single and dual agonist approaches, and what it means for the future of obesity and diabetes treatment.
Retatrutide in the Context of the GLP-1 Revolution
How retatrutide fits into the broader GLP-1 revolution that is transforming metabolic medicine, and what the competitive landscape means for the future of obesity and diabetes treatment.
Breaking Down the Phase 2 Obesity Results: What the Numbers Actually Mean
A detailed analysis of retatrutide's Phase 2 obesity trial data published in the New England Journal of Medicine, explaining what the key endpoints and results signify for the field.
How to Read Clinical Trial Data: A Practical Guide for Non-Scientists
An educational guide explaining how to interpret clinical trial results, including endpoints, statistical significance, effect sizes, and common pitfalls, using examples from metabolic medicine research.